TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron Limited ( (AU:IMC) ) has provided an announcement.
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference, highlighting the company’s advancements in biopharmaceuticals. This presentation underscores Immuron’s commitment to leveraging its proprietary technology to address infectious diseases, potentially enhancing its market position and offering significant benefits to stakeholders.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that specializes in developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases. The company is known for its product Travelan®, which is used to reduce the risk of travelers’ diarrhea, and it also focuses on developing treatments for Clostridioides difficile infection and irritable bowel syndrome.
Average Trading Volume: 186,272
Technical Sentiment Signal: Hold
Current Market Cap: A$23.43M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.